Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial

BACKGROUND: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tan, Darrell HS, Raboud, Janet M, Kaul, Rupert, Grinsztejn, Beatriz, Cahn, Pedro, Walmsley, Sharon L
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002348/
https://ncbi.nlm.nih.gov/pubmed/21106086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-11-113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados